Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

Fig. 5

Frequency of p.T790M acquisition in dependence on primary driver mutation. Frequency of total p.T790M acquisition in patients under reversible (a) and irreversible (b) EGFR TKI therapy for > 6 months, respectively. Frequency of p.T790M acquisition in EGFR Exon 19 mutated patients differs significantly in reversible and irreversible EGFR TKI treated patients determined by Qui Square test (p = 0.005)

Back to article page